1. Home
  2. DAC vs PHVS Comparison

DAC vs PHVS Comparison

Compare DAC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Danaos Corporation

DAC

Danaos Corporation

HOLD

Current Price

$117.30

Market Cap

2.1B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$28.41

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAC
PHVS
Founded
1972
2015
Country
Greece
Switzerland
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
DAC
PHVS
Price
$117.30
$28.41
Analyst Decision
Buy
Buy
Analyst Count
2
11
Target Price
$112.50
$41.82
AVG Volume (30 Days)
51.6K
214.6K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
3.06%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$79.48
$15.51
52 Week High
$120.00
$30.24

Technical Indicators

Market Signals
Indicator
DAC
PHVS
Relative Strength Index (RSI) 55.86 52.14
Support Level $91.64 $24.55
Resistance Level $118.58 $29.82
Average True Range (ATR) 2.73 1.42
MACD -0.12 -0.02
Stochastic Oscillator 61.77 56.08

Price Performance

Historical Comparison
DAC
PHVS

About DAC Danaos Corporation

Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: